BR112019000614A2 - derivados de quinazolinona inovadores de inibição de pi3k e composição farmacêutica contendo os mesmos - Google Patents
derivados de quinazolinona inovadores de inibição de pi3k e composição farmacêutica contendo os mesmosInfo
- Publication number
- BR112019000614A2 BR112019000614A2 BR112019000614-1A BR112019000614A BR112019000614A2 BR 112019000614 A2 BR112019000614 A2 BR 112019000614A2 BR 112019000614 A BR112019000614 A BR 112019000614A BR 112019000614 A2 BR112019000614 A2 BR 112019000614A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinazolinone derivatives
- innovative
- pharmaceutical composition
- pi3kd
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
a presente invenção se refere a derivados de quinazolinona inovadores de inibição de pi3k; um método para preparar os derivados; e uma composição farmacêutica para tratar neoplasmas hematológicos ou doenças do fígado, a qual contém os derivados de quinazolinona, em que os derivados de quinazolinona inovadores de acordo com a presente invenção têm um efeito benéfico no tratamento de neoplasmas hematológicos ou doenças do fígado. particularmente, os derivados de quinazolinona inibem pi3kd com alta seletividade em comparação com um fármaco anticâncer convencional de inibidores de pi3kd, reduzindo significativamente, desse modo, a imunotoxicidade ou inibindo simultaneamente pi3kd e pi3k¿, possibilitando, desse modo, o tratamento de doenças autoimunes e terapia anticâncer para câncer de sangue e similares. esses fármacos alvos têm uma vantagem de possibilitar que o problema dos efeitos colaterais de uma terapia anticâncer altamente tóxica convencional seja resolvido.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160089417 | 2016-07-14 | ||
| KR10-2016-0089417 | 2016-07-14 | ||
| KR1020170086691A KR101932146B1 (ko) | 2016-07-14 | 2017-07-07 | Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물 |
| KR10-2017-0086691 | 2017-07-07 | ||
| PCT/KR2017/007535 WO2018012907A1 (ko) | 2016-07-14 | 2017-07-13 | Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019000614A2 true BR112019000614A2 (pt) | 2019-04-24 |
Family
ID=60953246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019000614-1A BR112019000614A2 (pt) | 2016-07-14 | 2017-07-13 | derivados de quinazolinona inovadores de inibição de pi3k e composição farmacêutica contendo os mesmos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10577369B2 (pt) |
| EP (1) | EP3453393B1 (pt) |
| JP (2) | JP6614741B2 (pt) |
| KR (1) | KR101932146B1 (pt) |
| CN (1) | CN109475559B (pt) |
| AU (2) | AU2017297096B2 (pt) |
| BR (1) | BR112019000614A2 (pt) |
| CA (1) | CA3030692C (pt) |
| ES (1) | ES2824774T3 (pt) |
| GB (2) | GB2576120B (pt) |
| RU (2) | RU2019131147A (pt) |
| WO (1) | WO2018012907A1 (pt) |
| ZA (1) | ZA201900421B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101932146B1 (ko) * | 2016-07-14 | 2018-12-24 | 주식회사 바이오웨이 | Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물 |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| KR20210095495A (ko) | 2020-01-23 | 2021-08-02 | 주식회사 바이오웨이 | 신규한 퀴나졸리논 화합물 및 이를 포함하는 약학적 조성물 |
| CN111440173B (zh) * | 2020-03-27 | 2021-05-14 | 山东大学 | 一种pi3k抑制剂的制备方法 |
| CA3182133A1 (en) * | 2020-06-29 | 2022-01-06 | Council Of Scientific & Industrial Research | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof |
| KR20230065591A (ko) * | 2021-11-05 | 2023-05-12 | 연세대학교 산학협력단 | 피부-특이적 T 세포(skin-specific T cell)의 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| US20050054614A1 (en) * | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| US7932260B2 (en) * | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| CN101123968A (zh) * | 2004-06-04 | 2008-02-13 | 艾科斯有限公司 | 肥大细胞病的治疗方法 |
| CA2598409A1 (en) * | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| CN101575333B (zh) * | 2008-05-09 | 2011-06-22 | 和记黄埔医药（上海）有限公司 | 一种喹唑啉衍生物及其医药用途 |
| CA2975473C (en) | 2008-11-13 | 2021-01-19 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| US20130143902A1 (en) * | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| CN104768952B (zh) * | 2012-08-08 | 2016-10-19 | 山东亨利医药科技有限责任公司 | PI3Kδ抑制剂 |
| MY184292A (en) | 2013-09-22 | 2021-03-30 | Sunshine Lake Pharma Co Ltd | Substituted aminopyrimidine compounds and methods of use |
| WO2015061204A1 (en) * | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP2017502021A (ja) * | 2013-12-20 | 2017-01-19 | ギリアード カリストガ エルエルシー | ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法 |
| ES2763104T3 (es) | 2014-06-13 | 2020-05-27 | Gilead Sciences Inc | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-quinasa |
| KR101932146B1 (ko) * | 2016-07-14 | 2018-12-24 | 주식회사 바이오웨이 | Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물 |
-
2017
- 2017-07-07 KR KR1020170086691A patent/KR101932146B1/ko active IP Right Grant
- 2017-07-13 BR BR112019000614-1A patent/BR112019000614A2/pt not_active IP Right Cessation
- 2017-07-13 WO PCT/KR2017/007535 patent/WO2018012907A1/ko unknown
- 2017-07-13 EP EP17827977.4A patent/EP3453393B1/en active Active
- 2017-07-13 GB GB1915530.8A patent/GB2576120B/en not_active Expired - Fee Related
- 2017-07-13 ES ES17827977T patent/ES2824774T3/es active Active
- 2017-07-13 CN CN201780043603.1A patent/CN109475559B/zh not_active Expired - Fee Related
- 2017-07-13 RU RU2019131147A patent/RU2019131147A/ru unknown
- 2017-07-13 RU RU2019103684A patent/RU2702904C1/ru active
- 2017-07-13 GB GB1819957.0A patent/GB2570397B/en not_active Expired - Fee Related
- 2017-07-13 JP JP2019513840A patent/JP6614741B2/ja not_active Expired - Fee Related
- 2017-07-13 CA CA3030692A patent/CA3030692C/en active Active
- 2017-07-13 AU AU2017297096A patent/AU2017297096B2/en not_active Ceased
-
2019
- 2019-01-10 US US16/244,368 patent/US10577369B2/en not_active Expired - Fee Related
- 2019-01-21 ZA ZA2019/00421A patent/ZA201900421B/en unknown
- 2019-06-14 AU AU2019204181A patent/AU2019204181B2/en not_active Ceased
- 2019-11-01 JP JP2019199810A patent/JP2020040957A/ja active Pending
-
2020
- 2020-01-20 US US16/747,140 patent/US20200148684A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017297096B2 (en) | 2019-03-14 |
| GB2570397A (en) | 2019-07-24 |
| CN109475559B (zh) | 2020-06-23 |
| US10577369B2 (en) | 2020-03-03 |
| ZA201900421B (en) | 2020-05-27 |
| JP2020040957A (ja) | 2020-03-19 |
| GB2576120A (en) | 2020-02-05 |
| US20200148684A1 (en) | 2020-05-14 |
| CN109475559A (zh) | 2019-03-15 |
| JP6614741B2 (ja) | 2019-12-04 |
| KR20180008299A (ko) | 2018-01-24 |
| AU2017297096A1 (en) | 2019-01-31 |
| AU2019204181A1 (en) | 2019-07-04 |
| RU2702904C1 (ru) | 2019-10-14 |
| GB201819957D0 (en) | 2019-01-23 |
| WO2018012907A1 (ko) | 2018-01-18 |
| CA3030692C (en) | 2020-04-14 |
| EP3453393A4 (en) | 2019-06-26 |
| EP3453393A1 (en) | 2019-03-13 |
| EP3453393B1 (en) | 2020-09-09 |
| CA3030692A1 (en) | 2018-01-18 |
| KR101932146B1 (ko) | 2018-12-24 |
| US20190144453A1 (en) | 2019-05-16 |
| JP2019522678A (ja) | 2019-08-15 |
| AU2019204181B2 (en) | 2020-07-16 |
| GB201915530D0 (en) | 2019-12-11 |
| ES2824774T3 (es) | 2021-05-13 |
| GB2576120B (en) | 2020-07-29 |
| GB2570397B (en) | 2019-12-11 |
| RU2019131147A (ru) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019000614A2 (pt) | derivados de quinazolinona inovadores de inibição de pi3k e composição farmacêutica contendo os mesmos | |
| BR112022008535A2 (pt) | Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| BR112021022778A2 (pt) | Compostos e métodos para o tratamento de covid-19 | |
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| BR112015023948A2 (pt) | composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer | |
| BR112017018318A2 (pt) | composição farmacêutica para tratar câncer compreendendo microrna como ingrediente ativo | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
| BR112018011131A2 (pt) | terapia de combinação baseada em inibidores de sinal de pd-1 | |
| BR112018073786A2 (pt) | métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112017025698A2 (pt) | composições e métodos para inibir a expressão do gene de hif2alfa | |
| BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112018007128A2 (pt) | compostos para a inibição de câncer e epigênese | |
| BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
| BR112019024322A2 (pt) | Compostos e composições terapêuticos e métodos de uso dos mesmos | |
| Wang et al. | Azidothymidine inhibits cell growth and telomerase activity and induces DNA damage in human esophageal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2679 DE 10-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |